{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-025162","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.787016+00:00","generated_at":"2026-05-16T16:24:44.884788+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GT Biopharma receives Nasdaq delisting notice for low bid price","bullets":["Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.","Company has 180 calendar days until May 19, 2026 to regain compliance by closing at $1 for at least 10 consecutive business days.","If not cured, may qualify for additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to reverse split.","Company says it will monitor bid price and assess options; no assurance compliance will be regained."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-025162","json":"https://secwatch.observer/filing/0001493152-25-025162.json","markdown":"https://secwatch.observer/filing/0001493152-25-025162.md","text":"https://secwatch.observer/filing/0001493152-25-025162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315225025162/0001493152-25-025162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315225025162/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:24:44.884788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06fac0ac54061be3e4041faf3ceaa87029049438","claim":"GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its common stock, $0.001 par value per share (the “Common Stock”) had closed below $1 per share for 30 consecutive business days and, as a result, the Company was not in compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). This Letter has no immed","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315225025162/0001493152-25-025162-index.htm","confidence":0.99,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}